NBR1 (Neighbor of BRCA1 gene 1) is a selective autophagy receptor protein that plays a critical role in mediating the degradation of ubiquitinated cargoes via the autophagy-lysosome pathway. Structurally, it contains LC3-interacting regions (LIRs) and ubiquitin-associated (UBA) domains, enabling it to bind both autophagy machinery components (e.g., LC3/GABARAP proteins) and polyubiquitinated substrates. NBR1 functions similarly to p62/SQSTM1 but exhibits distinct substrate specificities, targeting protein aggregates, damaged organelles, and intracellular pathogens for autophagic clearance. It is also implicated in cellular stress responses, cancer progression, and neurodegenerative diseases.
NBR1 antibodies are essential tools for studying autophagy mechanisms, protein quality control, and disease pathology. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect NBR1 expression, localization, and interactions. Researchers employ them to investigate how NBR1 regulates autophagic flux under conditions such as nutrient deprivation, oxidative stress, or proteotoxic insults. Dysregulation of NBR1 has been linked to tumors, where it may act as an oncogene or tumor suppressor depending on context, as well as to Alzheimer’s and Parkinson’s diseases, where impaired autophagy contributes to pathogenic protein accumulation. Validated NBR1 antibodies ensure specificity for distinguishing NBR1 from homologous proteins like p62. aiding in accurate mechanistic studies. Their application advances understanding of autophagy-related pathways and potential therapeutic targets.